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Intestinal failure in childhood
Intestinal failure (IF) results from the critical reduction of functional gut 
mass below the minimal amount necessary for adequate digestion 
and absorption to satisfy body nutrient and fluid requirements for 
maintenance in adults or growth in children. IF requires parenteral 
nutrition (PN) for as long as it persists. 
Short bowel syndrome (SBS) was one of the first recognised 
conditions of protracted IF. With the increasing and successful use 
of long-term PN during the last three decades, several other causes 
of IF have emerged.
Long-term PN and home-PN are the mainstay of therapy, independent 
of the nature of “Intestinal failure” (IF) which can be total or partial, 
permanent or temporary.1–3 Some patients remain partially or almost 
fully dependent on PN for years or forever and are thus considered to 
have permanent IF. Complications of IF and/or PN limiting the use of 
long-term PN raise the question of intestinal transplantation (ITx).
Assessment of intestinal failure 
Citrulline, a non essential amino acid, mostly produced by enterocytes 
is a biological marker of functional gut mass.4,5 Studies performed 
in children with short bowel syndrome also emphasise the value of 
plasma citrulline as a biomarker of gut mass.6,7 Whether plasma 
citrulline levels are predictive of intestinal recovery, or not, remains 
to be confirmed. One of the best indicators for predicting full recovery 
of intestinal function remains the growth of the child as reflected in 
normal weight gain and growth velocity for age when fully, orally 
and/or enterally, fed. 
Causes of intestinal failure
Short bowel syndrome 
The incidence of SBS is difficult to establish, ranging between 
2 and 5 per million live births.8 The causes of SBS differ significantly 
between series (Table I).8–11 Necrotising enterocolitis (NEC) remains 
the leading cause of SBS especially in premature infants. The 
percentage of SBS caused by NEC ranges from 14 to 43% depending 
on the country that data originate from.9–13 Several studies included 
in a meta-analysis have shown that probiotics administration might 
be helpful in decreasing incidence of NEC in preterm infants.14 
Other causes of short bowel syndrome include resection following 
intestinal atresia, gastroschisis, other congenital malformation 
including midgut volvulus from malrotation, and radiation enteritis. 
Crohn’s disease should no longer be a cause of SBS resulting from 
repeated small bowel resection.
Survival of SBS infants has increased during the last decades. More 
than 80 % of infants and children now survive after extensive small 
bowel resection in the neonatal period.9,15 Prognosis is related to age 
adjusted intestinal length, ileocaecal valve (ICV), colon preservation 
and occurrence of cholestasis. In SBS patients most of the deaths 
are caused by liver failure or sepsis and occur within one year post-
event. A survey including 87 children who had undergone extensive 
neonatal SB resection, were followed up over a mean 15 year-period.9 
The overall survival was 89.7% depending on the year of birth. By 
multivariate analysis, PN duration was significantly influenced by the 
length of residual intestine and the absence of ileocaecal valve. After 
PN weaning, they grow up normally with normal puberty and final 
height as expected from genetic target height. 
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Nutritional support: In order to maintain an optimal nutritional status 
with normal growth and development oral feeding skills have to be 
acquired and maintained. PN is the corner stone of management 
but as much nutrition as possible should be provided to the patient 
via the enteral route in order to improve the physiological processes 
of intestinal adaptation. Oral feeding, which is known to enhance 
GI secretions, salivary Epidermal Growth Factor (EGF) release and 
gallbladder motility, is recommended. In addition, oral feeding 
by promoting gut motility improves intestinal bacterial clearance 
thus reducing the risk of small intestinal bacterial overgrowth.16 
However the mode of administration of feeding varies among 
different practitioners regarding the composition of the enteral feed 
(elemental, semi-elemental or polymeric) and mode of delivery 
(gastric tube feeding or oral feeding).17 Moreover current studies do 
not provide evidence based recommendations for using special diets 
such as amino acid based enteral formulae. Long term follow up of 
growth after PN weaning is mandatory in order to decide on the need 
to restart nutritional support, when required. 9 
Rehabilitation therapies for short bowel patients
Intestinal flora related disorders 
The colon is a crucial partner for small intestinal adaptation and 
function in patients who underwent extensive small intestinal 
resection.18 
However, colonic hypermetabolism may be responsible for D-lactic 
acidosis resulting from fermentation of dietary carbohydrate by 
luminal bacteria in the small bowel. D-lactic acidosis may be 
associated with clinical symptoms and failure to thrive.19 
Small bowel bacterial overgrowth (SBBO) is a frequent complication 
that is likely to occur in the case of ICV resection, poor motility of 
a dilated small bowel segment, or when a tight anastomosis is 
present. SBBO is mostly responsible for mucosal inflammation, 
which may further exacerbate nutrient malabsorption and protein 
sensitisation, deconjugate bile salts and deplete bile salt pool with 
subsequent impaired micellar solubilisation resulting in steatorrhea 
and fat soluble vitamins malabsorption. SBBO increases the risk of 
intestinal bacterial translocation which increases the risk for liver 
disease.20,21 
Antibiotic therapy should be used very cautiously and with due 
attention to their effects on the colonic bacterial microflora which 
should be preserved for production of short chain fatty acids. The 
use of probiotics might be helpful but it is not yet been adequately 
documented in SBS paediatric patients.22
Non-transplant surgery: Surgical procedures have been proposed 
for increasing nutrient and fluid absorption by either slowing the 
transit or increasing surface area. Such procedures include intestinal 
valves, reversed intestinal segments, colon interposition, but have all 
yielded conflicting results.23 
In selected patients with dilated bowel segments, longitudinal 
intestinal lengthening and tailoring (LILT) have been extensively 
performed.24 LILT has the theoretical benefit of not only tapering the 
dilated segment but also of using the divided intestine to increase 
total small bowel length. The anatomical criteria that have been 
suggested for patient selection for this procedure include (i) intestinal 
diameter (> 3 cm); (ii) length of residual small bowel (> 40 cm); 
and (iii) length of dilated bowel (> 20 cm). This procedure allows 
improvement in more than 50% of patients in terms of intestinal 
transit time, stool frequency, intestinal absorption rate, weight gain 
and PN weaning.25 LILI is not yet recommended for patients with 
severe liver disease or cirrhosis. 
Serial transverse enteroplasty (STEP) has also been reported for use 
in infants and children with SBS.26 Indications for the procedure have 
broadened STEP’s use beyond the scope of SBS to include bacterial 
overgrowth and neonatal intestinal obstruction with dilated proximal 
intestine. The first 38 patients enrolled in the International STEP 
Data Registry were reviewed.27 More data are requires to establish 
the long term safety and efficacy of the procedure, with the goal 
of improving patient selection criteria and optimal time of surgical 
intervention.
Trophic factors 
The use of recombinant human growth hormone (rhGH) is associated 
with conflicting results in adult patients with SBS who were included 
in both, open and/or randomised clinical trials.28,29 Few such studies 
have been reported in children with SBS.30,31 
Glucagon-like peptide-2 (GLP-2) has been reported to improve 
intestinal absorption and nutritional status in SBS patients with 
impaired postprandial GLP-2 secretion in whom the terminal ileum 
and the colon had been resected.32 The results of a paediatric study 
suggest that in infants with intestinal dysfunction, GLP-2 levels are 
correlated with residual small bowel length and nutrient absorption, 
and may be predictive of outcome33 GLP-2 might be the most logical 
medical approach for early management of SBS patients especially 
those with ileal resection. To date, there are no published studies 
involving infants or children.
Epidermal growth factor (EGF) has also been shown to have a role 
both in maintaining epithelial tissues as well as controlling intestinal 
adaptation.34 Five SBS paediatric patients (< 25% bowel length 
predicted for age) were treated with human recombinant EGF.35 
However, this study does not allow drawing any conclusion.
Insulin influences intestinal structure and absorptive function.36 The 
favourable effect of insulin is relevant and might be considered in 
patients on PN receiving high intravenous glucose rate that induce 
insulin release and relative hyperinsulinism. Interestingly, oral insulin 
has been shown to enhance intestinal adaptation following massive 
resection in a rat model.37 
Intestinal neuromuscular diseases
Total colonic aganglionosis (TIA) with jejuno-ileal involvement 
This condition is a rare form of Hirschsprung disease (HD). The 
aganglionosis may extend to encompass the entire colon (total 
colonic aganglionosis) or very rarely affect the entire intestine (TIA). 
When the normal ganglionic small bowel is shorter than 50 cm, 
the probability for permanent PN dependency is high. There is no 
surgical procedure that can improve intestinal absorption without 
the colon. Thus, TIA with jejuno-ileal involvement is equivalent to 
short bowel syndrome without colon. Small bowel transplantation 
is the ultimate cure. Several patients with a length of normal bowel 
segment ranging from 15 to 50 cm have been transplanted.38 
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Chronic intestinal pseudo-obstruction syndrome (CIPOS) 
This is a very heterogeneous condition in terms of clinical 
presentation, histopathological features, severity of motility disorders 
and outcome.39 Patients with the most severe form of CIPOS, whether 
myopathic or neuropathic with or without urinary tract involvement, 
are very uncomfortable because of the association of enterostoma, 
gastrostomy tube, central line and sometimes vesicostomy. ITx 
becomes logical, but difficult, because of the requirement of multiple 
previous surgical procedures and associated disorders such as 
uropathy or peripheral neuropathy.40 
Congenital enteropathy
Microvillous atrophy (MVA)
Among the causes of intractable diarrhoea of early infancy,41 MVA 
is a congenital constitutive intestinal epithelial cell disorder leading, 
in its typical early-onset form, to PIF. MVA is characterised by a lack 
of microvilli on the surface of enterocytes and the occurrence of 
intracellular vacuolar structures containing microvilli, Microvillous 
Inclusion Disease (MVID).42 Following homozygosity mapping in 
a single kindred with MVID, nonsense and missense mutations in 
MYO5B, encoding type Vb myosin motor protein were identified. In 
addition, mislocalisation of transferrin receptor in MVID enterocytes 
suggests that MYO5B deficiency causes defective trafficking of 
apical and basolateral proteins in MVID.43
The largest multi-centre survey of 23 MVA patients44 revealed an 
extremely reduced life expectancy with a one-year survival rate 
of less than 25%. Most children died of septic complications, liver 
failure or metabolic decompensation. Management is based on 
PN since all others medical approaches have failed. Complications 
related to inadequate PN do limit long-term survival. Finally, even 
with adequate long-term PN and normal growth, most children 
continue to manifest high and disabling levels of stool output that 
results in a high risk for severe dehydration and requires daily fluid 
and electrolyte replacement . Thus, ITx has become the only definitive 
treatment for this rare intestinal disease. ITx usually involves isolated 
intestine or intestine combined with the liver and colon.45 
Intestinal epithelial dysplasia (IED) or tufting enteropathy
Congenital tufting enteropathy (CTE) is a rare autosomal recessive 
diarrhoeal disorder presenting in the neonatal period. CTE is 
characterised by intestinal epithelial cell dysplasia leading to severe 
malabsorption and significant morbidity and mortality.46,47 The 
pathogenesis and genetics of this disorder are not well understood. 
Mutations in the gene for EpCAM are responsible for CTE.48 Several 
cases of CTE have been reported as being associated with phenotypic 
abnormalities such as choanal atresia, rectal atresia, esophageal 
atresia and a non-specific punctiform keratitis involving about 60% 
of patients. 
This cause of neonatal diarrhoea requires permanent PN. However, 
it would appear that some infants have a rather milder phenotype 
than others. Because of the preservation of some degree of 
intestinal function and a more limited volume of stool output, some 
patients need only partial long-term PN. Even in such cases, careful 
monitoring should be implemented in order to avoid progressive 
growth retardation. In most patients, the severity of intestinal 
malabsorption and diarrhoea, hoever, make such patients totally 
dependent on long-term PN with its attendant complications. In such 
patients intestinal transplantation may, thus, become an indication. 
Autoimmune enteropathy (AIE) causes severe IF.49 Mutations in the 
FOXP3 gene cause AIE.50 Non-functional FOXP3 leads to a tremendous 
hyperactivation of T cells, resulting in autoimmune aggression, such 
as seen in patients with immune dysregulation, polyendocrinopathy 
autoimmune enteropathy X-linked (IPEX) syndrome, a subgroup of 
AIE. The use of T-cell immunosuppressive drugs, such as tacrolimus 
or rapamycine following steroids treatment, seems to be beneficial in 
some patients. However, long-term remission is not always possible.51 
Bone marrow transplantation might be the treatment of choice in 
those patients who do not respond to immunosuppression.52,53 
From intestinal failure to intestinal transplantation
PN and home-PN remain the mainstay of therapy, independent of the 
nature of IF which can be total or partial, permanent or temporary.2,3,54 
However, some patients develop complications while receiving daily 
long-term PN for IF. These patients can be considered as candidates 
for intestinal transplantation. 
Intestinal failure-related liver disease 
Cholestasis and liver fibrosis are associated with impaired intestinal 
function, disruption of enterohepatic cycle (ileal disease or 
resection), intestinal stasis with subsequent intra-luminal bacterial 
overgrowth and/or translocation (endotoxinemia), recurrent catheter 
related sepsis, while prematurity itself might be an associated factor 
aggravated by inadequate PN.3 Preventing or reversing liver disease 
is possible by stimulating the enterobiliary axis by early oral/enteral 
feeding, by reducing intra-luminal bacterial overgrowth, by using 
ursodesoxycholic acid, by preventing catheter related sepsis, and 
by providing adapted PN with appropriate amino acids solutions, 
lipid emulsions, micronutrients provison and cyclic infusion.3 The 
guidelines on PN provide extensive recommendations for adapting 
nutritional support.54
Some SBS children with a length of remnant intestine theoretically 
sufficient to achieve PN weaning, liver disease interferes with 
gut adaptation and can lead to early death. The small size and 
poor condition of these infants means they are poor candidates 
for combined liver-intestine Tx, while many of them die before 
a combined graft is available. Case reports or small samples of 
isolated liver transplantation (ILTx) in SBS paediatric patients have 
been reported.55 Prevention of NEC, screening for high risk patients 
such as gastroschisis or NEC and prevention of IF related liver 
disease might improve outcome for such patients and decrease the 
need for any type of liver grafting alone or in combination with small 
intestine.3,56
Indications for Intestinal Transplantation
Some patients may remain partially or almost fully dependent on 
PN for years or forever and are thus considered to have permanent 
IF. Moreover, patients who develop complications while receiving 
daily long-term PN for IF are candidate for ITx. A European survey57 
studied the candidacy of home-PN patients for ITx and timing for 
referral for ITx. Candidacy was assessed by the USA Medicare and 
American Transplantation Society criteria,58,59 categorised as: 
(i)  life-threatening home parenteral nutrition (HPN) complications; 
(ii)  high risk of death due to the gastrointestinal disease; and 
(iii) IF with high morbidity or patient HPN refusal. 
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On the basis of these criteria, physicians judged candidacy for ITx 
as immediate or potential. The main indications for HPN were SBS 
(52%), chronic intestinal pseudoobstruction syndrome (CIPOS) (25%) 
and congenital mucosal disease (14.5%). Candidacy was considered 
for 57 patients (34.3%) with the following underlying disease: 
congenital enteropathy (26.3%), CIPOS (26.3%), SBS (19.3%). 
Immediate candidacy was judged for 15.8% of paediatric candidates 
(i.e < 50% of candidates because of HPN-related liver failure). 
The irreversibility of SBS related IF has to be demonstrated before 
any ITx can be considered. IF may be clearly and early considered 
as irreversible in patients with duodenocolic anastomosis after 
extensive intestinal resection for midgut volvulus or children with 
total aganglionosis with small bowel length less than 50 cm and 
infants suffering congenital enteropathy such as MVID or IED. All 
these patients are potential candidates for ITx. Since these patients 
will remain indefinitely dependent on PN, they must be referred early 
for transplantation on good nutrional status and with the minimal 
possible IF and PN related complications. Severe liver disease should 
no longer be considered as an indication for ITx. In contrast, it can be 
rather difficult to confirm irreversibility of IF in SBS or CIPOS patients 
for which all medical and/or surgical approaches have to be tried 
before any decision of ITx can be taken.3 In these particular cases, 
if long-term PN is effective and well-tolerated, it can be used for a 
prolonged period of time without ITx. Finally, few patients require 
immediate transplantation for life threatening conditions.57
Extensive multidisciplinary discussion involving transplant surgeons, 
paediatric gastroenterologists, specialised nurses, dieticians, social 
workers and psychologists is mandatory before any decision is taken 
for a specific child. Assessment and decisions should be based on 
the occurrence of the complications listed in the position paper of 
the American Society of Transplantation.60 
Type of intestinal transplantation
Children with severe advanced and progressive hepatic fibrosis 
are usually listed for LITx. However, some PN-dependent patients 
with advanced liver dysfunction may experience functional and 
biochemical liver recovery which appears to parallel autologous gut 
salvage.61,62
Factors impacting adversely on the survival of children with intestinal 
failure referred for ITx include : age below one year, multiple prior 
surgery, bridging fibrosis or cirrhosis, bilirubin levels over 3 mg/dl, 
and thrombocytopaenia.63 The United Network for Organ Sharing 
(UNOS) report indicates that mortality on the ITx waiting list is higher 
than on any other transplant waiting list.64 The ITx Registry confirmed 
that transplantations performed in patients waiting at home versus 
waiting in hospital have a better than one-year survival (74% versus 
59%; P < 0.00001).65 The trend to transplant proportionately more 
patients who are waiting at home was a major factor contributing 
to the recently improved graft and patient survival rates.65 Indeed, 
it is well established that patients with end stage liver disease are 
at risk of dying before transplantation and are also at higher risk 
of post-operative complications and death.63,64 We recently reported 
factors impacting on survival after Tx.66 Such factors should also be 
considered before listing a patient for ITx.
Intestinal failure rehabilitation centre
Long-term management of IF has become a very important goal. Few 
centres manage all the stages of IF from onset to ITx, including home 
PN programmes.2,67 SBS remains the most common indication for ITx 
accounting for 63% of case versus 32% of other indications in our 
transplantation centre.65,66 Liver complications of poor functioning 
remnant small intestine with intestinal stasis and subsequent sepsis 
from bacterial overgrowth may be prevented by appropriate medico-
surgical approaches. In addition to the prevention of complications, 
global management should also aim to demonstrate the irreversibility 
of IF in spite of all medico-surgical attempts at digestive autonomy.3
The development of integrated centres involved in all stage of IF 
management should be encouraged. Such centres should have a 
high level of expertise in the fields of paediatric Gastroenterology 
and Clinical Nutrition with a well organised Home-PN programme, 
together with experienced paediatric surgeons involved in SBS-non-
transplant surgery as well as in intestinal transplantation.67,68 ITx 
offers not only an improved quality of life but also maintains optimal 
nutritional status.69,70
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